FDA Grants Breakthrough Therapy Designation to Servier’s B7-H4 ADC for Adenoid Cystic Carcinoma

Servier announced that the FDA has granted Breakthrough Therapy designation to emiltatug ledadotin (Emi-Le), an investigational antibody-drug conjugate (ADC) targeting B7-H4 for the treatment of patients with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (ACC) with solid histology or high-grade transformation.¹

The designation marks an important regulatory milestone for the rare cancer program and underscores increasing industry focus on targeted therapies for difficult-to-treat solid tumors with limited approved treatment options. ACC is a rare malignancy that most commonly develops in the salivary glands and is associated with frequent recurrence and metastatic progression.²

Currently, there are no FDA-approved systemic therapies specifically indicated for advanced or metastatic ACC, leaving surgery and radiation as the primary treatment approaches for many patients.

Rare Cancer Patients Face Limited Treatment Options

ACC affects approximately four individuals per million annually and can occur in secretory glands throughout the body, though it is most frequently diagnosed in the head and neck region.² While the disease often progresses slowly initially, recurrence rates remain high, and metastatic disease can become aggressive and difficult to manage.²

Servier stated that the FDA’s Breakthrough Therapy designation is intended to accelerate the development and review of investigational therapies that may demonstrate substantial improvement over existing treatment options for serious diseases.¹ The designation may enable closer FDA collaboration, rolling review, and potential eligibility for expedited approval pathways.³

“At Servier, we are committed to pursuing first-in-class medicines for rare diseases in oncology,” said Peter Adamson, global head of oncology clinical development at Servier, in the company announcement.¹ “This Breakthrough Therapy designation for Emi-Le will help accelerate development and may provide an important new treatment option for patients with few effective choices today.”¹

B7-H4 Emerges as an ADC Target

Emi-Le is a B7-H4-directed ADC incorporating Servier’s Dolasynthen platform technology and a proprietary auristatin-F hydroxypropylamide payload.¹ The investigational therapy was designed with a target-optimized drug-to-antibody ratio intended to improve delivery precision while controlling bystander effects.¹

B7-H4 has emerged as an increasingly attractive oncology target because of its overexpression across multiple tumor types and relatively limited presence in healthy tissues.⁴ Researchers are evaluating B7-H4-directed therapies across gynecologic malignancies, breast cancer, and salivary gland cancers, among others.⁴

Servier noted that Emi-Le is currently being evaluated in an ongoing multicenter Phase 1 clinical trial involving patients with ACC and other solid tumors, including breast, ovarian, and endometrial cancers.¹ Initial findings from the study demonstrated manageable safety and confirmed objective responses across multiple tumor types.¹

The investigational ADC has also previously received FDA Fast Track designation for advanced or metastatic triple-negative breast cancer and HER2-low/HER2-negative breast cancers following prior topoisomerase-1 ADC treatment.¹

ADC Development Continues to Accelerate

The Breakthrough Therapy designation reflects broader momentum within the ADC sector, which has become one of the most active areas in oncology drug development. Pharmaceutical companies are increasingly investing in ADC technologies designed to improve tumor targeting while minimizing systemic toxicity associated with conventional chemotherapy.

Recent years have seen a wave of regulatory approvals and licensing deals involving next-generation ADC platforms targeting both common and rare cancers.⁴ Industry analysts expect continued growth in the field as developers pursue novel targets and combination approaches involving immunotherapies and precision oncology agents.⁴

For patients with advanced ACC, the FDA designation may represent a significant step toward expanding therapeutic options in a disease setting where innovation has historically been limited and clinical outcomes remain poor.

References

1. Emiltatug ledadotin (Emi-Le) granted Breakthrough Therapy designation by the U.S. FDA for adenoid cystic carcinoma (ACC). (2026, May 12). PR Newswire. https://prnmedia.prnewswire.com/news-releases/emiltatug-ledadotin-emi-le-granted-breakthrough-therapy-designation-by-the-us-fda-for-adenoid-cystic-carcinoma-acc-302769049.html
2. Understanding ACC. Adenoid Cystic Carcinoma Research Foundation. https://accrf.org/living-with-acc/understanding-acc/
3. US Food and Drug Administration. (2023). Breakthrough therapy designation. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy
4. Phipps, M., & Falchook, G. S. (2025, Apr 10). B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A Review. Journal of immunotherapy and precision oncology. https://doi.org/10.36401/JIPO-24-34